Pioglitazone Decreases Visceral Fat Metabolism

Effects of Pioglitazone on Visceral Fat Metabolic Activity

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01819402

Enrollment

Registered

2013-03-27

Start date

2012-03-31

Completion date

Unknown

Last updated

2013-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

To Evaluate the Effect of Pioglitazone on Glucose Metabolism of Fat Tissue by Using FDG-PET/CT Imaging

Keywords

visceral fat metabolism; FDG-PET/CT; pioglitazone; glimepiride; adiponectin

Brief summary

Excess visceral fat is associated with chronic systemic inflammation and cardiovascular complications. Pioglitazone has been reported to variably influence visceral fat volume, but it its effect on metabolic activity of the visceral fat remains uncharacterized. To evaluate the effect of pioglitazone on glucose metabolism of fat tissue by using 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) and computed tomography (CT) imaging.

Interventions

DRUGPioglitazone vs Glimepiride

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

35 Years to 58 Years

Healthy volunteers

Yes

Inclusion criteria

* Subjects between the ages of 35 and 85 years * Subjects with impaired glucose tolerance and type 2 diabetes

Exclusion criteria

* Subjects with insulin treatment * Subjects with uncontrolled diabetes, hypertension, symptomatic coronary artery disease, symptomatic cerebrovascular disease * Subjects taking more than three antidiabetic medications * Subjects taking anti-platelet, statins, antidiabetic agents, thiazolidinediones within 8 weeks prior to randomization * Subjects with cardiac failure (New York Heart Association Class \> III) or left ventricular dysfunction (LVEF \< 40%) * Subjects with systemic disorders such as active inflammatory, liver, renal, hematopoietic, and malignant disease

Design outcomes

Primary

Measure	Time frame
Effect of treatment on the nominal change in FDG uptake of fat tissue from baseline after 16 weeks of treatment as measured by FDG-PET/CT imaging.	Baseline and 16 weeks after treatment

Secondary

Measure	Time frame
Change from baseline in plasma glucose/insulin homeostatic parameters and circulating inflammatory markers	Baseline and 16 weeks after treatment

Other

Measure	Time frame
All cardiovascular events and all cause death for 5 years	Baseline and 5 years after treatment

Countries

Japan

Contacts

Primary ContactNobuhiro Tahara, MD, PhD

ntahara@med.kurume-u.ac.jp+81-942-31-7580

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026